<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534910</url>
  </required_header>
  <id_info>
    <org_study_id>21567-01</org_study_id>
    <nct_id>NCT01534910</nct_id>
  </id_info>
  <brief_title>Effect of Aged Garlic Extract on Atherosclerosis</brief_title>
  <acronym>Garlic4</acronym>
  <official_title>Effect of Aged Garlic Extract on Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Los Angeles Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wakunaga Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Los Angeles Biomedical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be assessing the effect of Aged Garlic Extract on the coronary
      arteries. The investigators will enroll patients in a double blind study, where half the
      patients will receive placebo, and have the patients undergo a series of tests of plaque (CT
      scan of the heart, carotid ultrasound) and follow the patients on the drug or placebo and
      then repeat the tests and blood work at the end of one year. The investigators will assess if
      being on aged garlic extract adds any benefit to plaque in the coronary or neck arteries. The
      investigators will also assess the effect of aged garlic extract on markers of inflammation.
      Patients will receive free drug, free testing and be compensated, and learn more about their
      heart and neck arteries. if successful, more patients can use this drug to benefit their
      health. The harms include the radiation from the CT scan and the medication, which has mild
      side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will be assessing the effect of Aged Garlic Extract on the coronary
      arteries. The investigators will enroll patients in a double blind study, where half the
      patients will receive placebo, and have the patients undergo a series of tests of plaque (CT
      scan of the heart, carotid ultrasound) and follow the patients on the drug or placebo and
      then repeat the tests and blood work at the end of one year. The investigators will assess if
      being on aged garlic extract adds any benefit to plaque in the coronary or neck arteries. The
      investigators will also assess the effect of aged garlic extract on markers of inflammation.
      Patients will receive free drug, free testing and be compensated, and learn more about their
      heart and neck arteries. if successful, more patients can use this drug to benefit their
      health. The harms include the radiation from the CT scan and the medication, which has mild
      side effects. The study will perform advanced CT angiography at baseline and follow up along
      with carotid intimal media thickness testing, to see if plaque is slowed down by Aged Garlic
      Extract
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT Angiography Plaque</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>we will measure low attenuation plaque at baseline (in volume) and then again at 1 year. we will assess if there is a reduction in low attenuation plaque volume (percent change from baseline), defined as [followup-baseline]/baseline x100%.
Baseline was time zero, followup CT scan was 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Calcium</measure>
    <time_frame>1 year</time_frame>
    <description>Agatston score is a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an unenhanced low-dose CT scan. The calculation is based on the weighted density score given to the highest attenuation value (HU) multiplied by area of the calcification speck. The grading of coronary artery disease (based on total calcium score) is as follows: no evidence of CAD: 0 calcium score, minimal: 1-10, mild: 11-100, moderate: 101-400, and severe: &gt;400</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aged Garlic Extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400 mg of aged garlic extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aged garlic extract</intervention_name>
    <description>2400 mg a day</description>
    <arm_group_label>Aged Garlic Extract</arm_group_label>
    <other_name>Kyolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 40-65 years

          -  Framingham risk score 6-20%, and at least 2 components of the metabolic syndrome as
             defined by ATP III Clinical Identification of the Metabolic Syndrome (including
             impaired fasting glucose &gt; 110 mg/dl, treated hypertension or SBP &gt; 130 or DBP &gt; 85 mm
             Hg, plasma triglycerides &gt; 150 mg/dl, HDL cholesterol &lt; 35 mg/dl for men or &lt; 40 mg/dl
             for women, abdominal obesity as defined as waist &gt; 40 in for men, &gt; 35 in for women)

          -  Subjects must provide written informed consent after the scope and nature of the
             investigation has been explained to them

          -  Subjects should be stable on their concomitant medications for at least 26 weeks prior
             to randomization

          -  Calcium Score &gt; 20 at baseline

          -  Subjects who agree to refrain from other anti-glycemic agent Exclusion Criteria

          -  A contraindication to AGE including: known hypersensitivity to drug.

          -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of
             the investigator or principal investigator is likely to affect the subject's ability
             to complete the study or precludes the subject's participation in the study

          -  Weight in excess of 300 pounds

          -  Bleeding disorder

          -  History of known coronary artery disease, myocardial infarction, stroke or
             life-threatening arrhythmia within the prior six months

          -  NYHA Class II- IV heart failure

          -  History of malignancy within the last 5 years (other than skin cancer) or evidence of
             active cancer which would require concomitant cancer chemotherapy

          -  Serum creatinine &gt; 1.4 mg/dl

          -  Diabetes Mellitus

          -  Triglycerides &gt; 400 at visit 1

          -  Drug or alcohol abuse, or current intake of more than 14 standard drinks per week

          -  Concurrent enrollment in another placebo-controlled trial

          -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption

          -  Current diabetes or intake of anti-diabetic or other prohibited drug

          -  Current tobacco use

          -  Current use of anticoagulants (except for anti-platelet agents)

          -  Renal failure

          -  History of hypertensive encephalopathy or cerebrovascular accident

          -  Hematological or biochemical values at screening outside the reference ranges
             considered as clinically significant in the opinion of the investigator or PI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>February 20, 2015</results_first_submitted>
  <results_first_submitted_qc>March 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2015</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>garlic</keyword>
  <keyword>ct angiography</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>carotid IMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>all 65 participants were recruited</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>placebo
placebo: placebo</description>
        </group>
        <group group_id="P2">
          <title>Aged Garlic Extract</title>
          <description>2400 mg of aged garlic extract
aged garlic extract: 2400 mg a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>placebo
placebo: placebo patients were randomized to placebo</description>
        </group>
        <group group_id="B2">
          <title>Aged Garlic Extract</title>
          <description>2400 mg of aged garlic extract
aged garlic extract: 2400 mg a day patients randomized to aged garlic extract</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="7"/>
                    <measurement group_id="B2" value="56" spread="8"/>
                    <measurement group_id="B3" value="57" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CT Angiography Plaque</title>
        <description>we will measure low attenuation plaque at baseline (in volume) and then again at 1 year. we will assess if there is a reduction in low attenuation plaque volume (percent change from baseline), defined as [followup-baseline]/baseline x100%.
Baseline was time zero, followup CT scan was 1 year.</description>
        <time_frame>baseline to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>placebo
placebo: placebo patients were randomized to placebo No adverse events</description>
          </group>
          <group group_id="O2">
            <title>Aged Garlic Extract</title>
            <description>2400 mg of aged garlic extract
aged garlic extract: 2400 mg a day patients randomized to aged garlic extract No adverse events</description>
          </group>
        </group_list>
        <measure>
          <title>CT Angiography Plaque</title>
          <description>we will measure low attenuation plaque at baseline (in volume) and then again at 1 year. we will assess if there is a reduction in low attenuation plaque volume (percent change from baseline), defined as [followup-baseline]/baseline x100%.
Baseline was time zero, followup CT scan was 1 year.</description>
          <units>percent change of low attenuation plaque</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.97"/>
                    <measurement group_id="O2" value="-1.53" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coronary Calcium</title>
        <description>Agatston score is a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an unenhanced low-dose CT scan. The calculation is based on the weighted density score given to the highest attenuation value (HU) multiplied by area of the calcification speck. The grading of coronary artery disease (based on total calcium score) is as follows: no evidence of CAD: 0 calcium score, minimal: 1-10, mild: 11-100, moderate: 101-400, and severe: &gt;400</description>
        <time_frame>1 year</time_frame>
        <population>patients undergoing two calcium scores</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>placebo
placebo: placebo</description>
          </group>
          <group group_id="O2">
            <title>Aged Garlic Extract</title>
            <description>2400 mg of aged garlic extract
aged garlic extract: 2400 mg a day</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Calcium</title>
          <description>Agatston score is a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an unenhanced low-dose CT scan. The calculation is based on the weighted density score given to the highest attenuation value (HU) multiplied by area of the calcification speck. The grading of coronary artery disease (based on total calcium score) is as follows: no evidence of CAD: 0 calcium score, minimal: 1-10, mild: 11-100, moderate: 101-400, and severe: &gt;400</description>
          <population>patients undergoing two calcium scores</population>
          <units>agatston units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="74" upper_limit="116"/>
                    <measurement group_id="O2" value="49" lower_limit="20" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>placebo
placebo: placebo patients were randomized to placebo No adverse events</description>
        </group>
        <group group_id="E2">
          <title>Aged Garlic Extract</title>
          <description>2400 mg of aged garlic extract
aged garlic extract: 2400 mg a day patients randomized to aged garlic extract No adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Matthew Budoff</name_or_title>
      <organization>Los Angeles Biomedical Research Institute</organization>
      <phone>310-222-4107</phone>
      <email>mbudoff@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

